The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity

• Published in: British journal of cancer Vol. 126; no. 8; pp. 1168 - 1177
• Main Authors: Edwards, Carolyn J., Sette, Angelica, Cox, Carl, Di Fiore, Barbara, Wyre, Chris, Sydoruk, Daniela, Yadin, David, Hayes, Philip, Stelter, Szymon, Bartlett, Phillip D., Zuazo, Miren, Garcia-Granda, Maria Jesus, Benedetti, Giovanni, Fiaska, Stratoniki, Birkett, Neil R., Teng, Yumin, Enever, Carrie, Arasanz, Hugo, Bocanegra, Ana, Chocarro, Luisa, Fernandez, Gonzalo, Vera, Ruth, Archer, Bethan, Osuch, Isabelle, Lewandowska, Martyna, Surani, Yasmin M., Kochan, Grazyna, Escors, David, Legg, James, Pierce, Andrew J.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group 03.05.2022; Nature Publishing Group UK
• Subjects: Avidity; Cancer immunotherapy; Cell growth; Cell proliferation; Immunotherapy; Lung cancer; Lymphocytes; Lymphocytes T; Major histocompatibility complex; Non-small cell lung carcinoma; Patients; PD-1 protein; PD-L1 protein; Pharmacokinetics; Tumors

Abstract Background Improving cancer immunotherapy long-term clinical benefit is a major priority. It has become apparent that multiple axes of immune suppression restrain the capacity of T cells to provide anti-tumour activity including signalling through PD1/PD-L1 and LAG3/MHC-II. Methods CB213 ha...